Results 51 to 60 of about 181,087 (306)

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

Frontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiexiong Wu, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Ting Su, Ting Su, Ting Su, Ting Su, Ting Su, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +33 more
doaj   +1 more source

Targeting the tumor microenvironment in colorectal peritoneal metastases

, 2020
Peritoneal metastasis (PM) occurs in approximately one in four colorectal cancer (CRC) patients. The pathophysiology of colorectal PM remains poorly characterized. Also, the efficacy of current treatment modalities, including surgery and intraperitoneal (
Ceelen, Wim, De Wever, Olivier, Heriot, Alexander G., Narasimhan, Vignesh, Ramsay, Robert G.   +4 more
core   +1 more source

Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer. [PDF]

, 2017
INTRODUCTION: Colorectal cancer remains the second leading cause of cancer death in the United States, and new strategies to prevent, detect, and treat the disease are needed.
Aka, Allison A., Pattison, Amanda M., Rappaport, Jeff A., Sato, Takami, Snook, Adam E., Waldman, Scott A.   +5 more
core   +2 more sources

Chimeric antigen receptor–engineered T cells for liver cancers, progress and obstacles

Tumor Biology, 2017
Chimeric antigen receptor–engineered T cells therapy has become the hottest topic of immunotherapy, as its great successes achieved in treating refractory hematological malignancies.
Keyu Li, Yaliang Lan, Jiabei Wang, Lianxin Liu   +3 more
doaj   +1 more source

Improved induction of anti-melanoma T cells by adenovirus-5/3 fiber modification to target human DCs [PDF]

, 2018
To mount a strong anti-tumor immune response, non T cell inflamed (cold) tumors may require combination treatment encompassing vaccine strategies preceding checkpoint inhibition.
Chondronasiou, Dafni, Curiel, David T, de Gruijl, Tanja D, Dmitriev, Igor, Eisden, Tracy-Jane T. H. D, Hooijberg, Erik, Icyuz, Mert, Matthews, Qiana L, Stam, Anita G.M, van de Ven, Rieneke   +9 more
core   +3 more sources

Organoids in pediatric cancer research

FEBS Letters, EarlyView.
Organoid technology has revolutionized cancer research, yet its application in pediatric oncology remains limited. Recent advances have enabled the development of pediatric tumor organoids, offering new insights into disease biology, treatment response, and interactions with the tumor microenvironment.
Carla Ríos Arceo, Jarno Drost
wiley   +1 more source

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Zhongliu Fangzhi Yanjiu, 2022
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors.
JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun   +5 more
doaj   +1 more source

Development of novel adenoviral vectors to overcome challenges observed with HAdV-5 based constructs [PDF]

, 2011
Recombinant vectors based on human adenovirus serotype 5 (HAdV-5) have been extensively studied in pre-clinical models and clinical trials over the last two decades.
Julio Alonso-Padilla, Tibor Papp, Győző L Kaján, Mária Benkő, Menzo Havenga, Angelique Lemckert, Balázs Harrach, Andrew H Baker, Harrach, Benkő, Liu, Reddy, Benevento, Reddy, Rux, Bergelson, Wickham, Wolfrum, Arnberg, Burckhardt, Vectors used in gene therapy clinical trials., Appaiahgari, Pearson, Wilson, Chorny, Van Kampen, George, Ranki, Hendrickx, Ilan, Schaack, Aldhamen, Machitani, Appledorn, Perreau, Minamitani, Khare, Lyons, Carlisle, Seiradake, Xu, Khare, Qiu, Waddington, Kalyuzhniy, Vigant, Alba, Jonsson, Lenman, Doronin, Xu, Eichholz, Ganesan, Alemany, Piccolo, Mocanu, Piccolo, Khare, Xu, Lasaro, Zak, Zhang, Barouch, Bradley, Roberts, Gall, Fausther-Bovendo, Sumida, Miyazawa, Teigler, Smith, Molinier-Frenkel, Heemskerk, Hutnick, Tang, Olive, Leen, Joshi, Osada, Perreau, Seregin, Seregin, Fontanellas, Cerullo, Brunetti-Pierri, Seregin, Farrow, McConnell, Belousova, Seregin, Capasso, Green, Doronin, Kreppel, Matsui, Suzuki-Kouyama, Prill, Krasnykh, Zabner, Havenga, Lecollinet, Coughlan, Granio, Parker, Guse, Smith, Nicol, Bruder, Bruder, Baden, Coughlan, Mück-Häusl, Bi, Abbink, Abbink, Mastrangeli, Abrahamsen, Brough, Stone, Sirena, Stone, Seshidhar Reddy, Hemminki, Creech, Vogels, Kuhn, Di, Havenga, Kahl, Vogels, Lemckert, Teigler, Tameris, Ouédraogo, Keefer, Baden, Gilbert, Baden, Zahn, Johnson, Dakin, Alexander, Alexander, Gurwith, Lemiale, Jarecki-Khan, Saderi, Ko, Bangari, Ayalew, Hammond, Tuboly, Fischer, Hu, Greenall, Brake, Lopez-Gordo, Kremer, Soudais, Soudais, Silva, Puig, Fernandes, Tandon, Bangari, Nguyen, Lenaerts, Ying, van Olphen, Zakhartchouk, Cauthen, Reddy, Reddy, Li, Lenaerts, Sharma, Sharma, Roy, Cohen, Xiang, Quinn, Farina, Roy, Colloca, Barnes, O'Hara, Antrobus, Stanley, Tan, Michou, Ojkic, Sheppard, Corredor, Cherenova, Shashkova, Logunov, Both, Xu, Khatri, Hofmann, Löser, Both, Martiniello-Wilks, Tang, Fraser, Bridgeman, Doszpoly, Cortés-Hinojosa, Wigand, Kajon, Guy, Benkö, Lu, Günes, Wellehan, Phan   +215 more
core   +4 more sources

Hematopoietic (stem) cells—The elixir of life?

FEBS Letters, EarlyView.
The aging of HSCs (hematopoietic stem cells) and the blood system leads to the decline of other organs. Rejuvenating aged HSCs improves the function of the blood system, slowing the aging of the heart, kidney, brain, and liver, and the occurrence of age‐related diseases.
Emilie L. Cerezo, Jonah Anderson, Emilie Dinh Vedrenne, Noël Yeh Martín, Jette Lengefeld   +4 more
wiley   +1 more source

Investigating the cell of origin and novel molecular targets in Merkel cell carcinoma: a historic misnomer

Molecular Oncology, EarlyView.
This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian, Sriraam Sivachandran, Melissa Galati, Brandon Ramchatesingh, Hibo Rijal, Johnny Hanna, Elena Netchiporouk, May Chergui, Margaret Redpath, Samy Abou Setah, Ivan V. Litvinov   +10 more
wiley   +1 more source